Advertisement

Response to the Letter from Dr. Jacob Peedicayil

  • Kenji Sakuma
  • Taro Kishi
  • Nakao Iwata
Letter to the Editor
  • 6 Downloads

Notes

Acknowledgments

We thank Dr. Donald C. Goff (Marvin Stern Professor, Vice Chair for Research, Department of Psychiatry, NYU Langone Medical Center, NY, USA), Dr. Eric A. Macklin (MGH Biostatistics Center, Boston, MA, USA), and Dr. William M. Greenberg (St. George’s University School of Medicine, True Blue, Grenada, Mental Health Association of Rockland County, Valley Cottage, NY, USA) for providing information relevant to this study.

Contributors

The manuscript was written by all authors.

Compliance with ethical standards

Conflicts of interest

Drs. Sakuma, Kishi, and Iwata declare that they have no direct conflicts of interest relevant to this study.

Dr. Sakuma has received speaker’s honoraria from Otsuka.

Dr. Kishi has received speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, Tanabe-Mitsubishi, and Yoshitomi and has received a Health Labour Sciences Research Grant and a Fujita Health University School of Medicine research grant.

Dr. Iwata has received speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has received research grants from GlaxoSmithKline, Meiji, and Otsuka.

References

  1. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, Corvin A, Cichon S, Sullivan PF (2015) Evaluating historical candidate genes for schizophrenia. Mol Psychiatry 20:555–562CrossRefPubMedPubMedCentralGoogle Scholar
  2. Hu CY, Qian ZZ, Gong FF, Lu SS, Feng F, Wu YL, Yang HY, Sun YH (2015) Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis. J Neural Transm (Vienna) 122:307–320CrossRefGoogle Scholar
  3. Misiak B, Laczmanski L, Sloka NK, Szmida E, Piotrowski P, Loska O, Slezak R, Kiejna A, Frydecka D (2016) Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism. Psychiatry Res 238:60–67CrossRefPubMedGoogle Scholar
  4. Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N (2018) Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology 235:2303–2314CrossRefPubMedGoogle Scholar
  5. Wang W, Fan W, Shi B, Tong C, Wang X, Cai J, Zhang C (2017) Effect of MTHFR gene on the schizophrenia and its cognitive function. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 34:905–908PubMedGoogle Scholar
  6. Yoshimi A, Aleksic B, Kawamura Y, Takahashi N, Yamada S, Usui H, Saito S, Ito Y, Iwata N, Inada T, Noda Y, Yamada K, Ozaki N (2010) Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res 124:216–222CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychiatryFujita Health University School of MedicineToyoakeJapan

Personalised recommendations